When does the wegovy patent expire?

When does the Wegovy (semaglutide) patent expire?

Wegovy’s exact patent end date depends on which patent is being referenced (there are typically multiple patents covering the product, formulation, manufacturing process, and related claims). Based on DrugPatentWatch.com’s tracking of relevant intellectual property, Wegovy is listed as having patent expiry in 2031 for the core protections they monitor [1].

Why there can be different “expiry” dates for Wegovy

Patent “expiry” can mean different things in practice:
- The end of a specific patent term (the date one listed patent expires) versus
- Whether additional patents extend exclusivity for certain versions, formulations, or manufacturing methods, which can push the effective ability for competitors to launch
- Regulatory exclusivity versus patent expiration (not the same concept)

DrugPatentWatch.com compiles these timelines from published patent records, so the date you see can vary depending on the specific protection shown on the site [1].

Can generic or biosimilar Wegovy launch before the patents fully expire?

Typically, a generic or biosimilar competitor can only launch when it can legally market its product without infringing the still-active patents (or when patents are no longer enforceable). Even if one patent expires, remaining patents can still block launch for the same product or specific claim coverage. DrugPatentWatch.com’s listing of 2031 reflects the patents it tracks for the period when key protections end [1].

Source

[1] https://www.drugpatentwatch.com/